You are here

Screens for Identifying HIV Fusion Inhibitors

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1 R43 AI38157-01,
Agency Tracking Number: 29124
Amount: $734,787.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1997
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
4727 University Drive
Durham, NC 27707
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Dennis Lambert
 () -
Business Contact
Phone: () -
Research Institution
N/A
Abstract

A synthetic peptide, DP-178, representing a discrete region of the HIV fusion protein, gp4l, effectvirus-mediated cell to cell fusion as well as de novo virus infection of T-cells (2). DP-178 has beeselectively to soluble forms of HIV-1 gp41 from which it was derived (4). While DP-178 is promisingtherapeutic, it may exhibit a limited delivery profile characteristic of peptide therapeutics. Theresmall molecule mimic of DP-178, by exploiting the selective binding of this peptide to soluble formsobjectives are to discover and develop a novel class of antivirals for the treatment of HIV infectiodevelop a high through-put biochemical screen based on the binding of DP-178 to gp41 analogs as a finew antiviral leads. Our specific aims are (1) to develop an antibody-based biochemical binding assathrough-put screen; (2) to develop a direct binding biochemical assay suitable as a high through-putcell-based gp41 binding and fusion assay suitable as a high through-put screen; (4) to identify sourscreening.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government